Profile
Company facts
- Exchange
- LSE
- Currency
- GBP
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- GB00BMWLM973
- Market cap
- 31M
- P/E ratio
- 40.5
- Analyst target
- 275.5
- Dividend yield
- Not available
- Beta
- -0.19
About
About Arecor Therapeutics PLC
Arecor Therapeutics plc, a clinical stage biotechnology company, develops therapeutics that address diabetes, obesity and other cardiometabolic diseases in the United Kingdom. The company's lead therapeutic product is the AT278, a disruptor insulin which is designed to transform Automated Insulin Delivery (AID) systems to improve patient care for people living with diabetes. It also develops a novel oral delivery platform using a GLP-1 receptor agonist. Arecor Therapeutics plc was founded in 2007 and is headquartered in Little Chesterford, the United Kingdom.
Visit company website
No comments yet
Start a focused discussion about AREC.LSE.